 placebo-control trial mainten therapi fluconazol treatment cryptococc mening acquir immunodefici syndrom california collabor treatment group background and method patient acquir immunodefici syndrom aid rate relaps primari treatment cryptococc mening high double-blind trial efficaci mainten therapi fluconazol entri studi particip steril cultur cerebrospin fluid blood urin standard cours therapi culture-prov cryptococc mening patient fluconazol placebo mainten therapi dose fluconazol mg first phase studi mg second phase result patient percent silent persist infect basi cultur posit entri studi patient follow-up entri patient percent percent recurr cryptococc infect site differ risk percent percent confid interv recurr infect urin prostat massag recurr mening infect patient placebo none fluconazol mean durat follow-up day multivari analys predictor recurrence-fre surviv fluconazol treatment rel hazard serum cryptococcal-antigen titer rel hazard prolong primari therapi flucytosin rel hazard surviv toxic similar maintenance-treat group conclus patient aid silent persist infect common success treatment cryptococc mening mainten therapi fluconazol effect recurr cryptococc infect